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Biomarkers in Pulmonary Embolism
Elevated Heart-Type Fatty Acid-Binding Protein
Levels on Admission Predict an Adverse Outcome in
Normotensive Patients With Acute Pulmonary Embolism
Claudia Dellas, MD, Miriam Puls, MD, Mareike Lankeit, MD, Katrin Schäfer, MD,
Mayumi Cuny, MD, Maik Berner, MD, Gerd Hasenfuss, MD, Stavros Konstantinides, MD
Goettingen, Germany
Objectives We assessed the predictive value of heart-type fatty acid-binding protein (H-FABP) in normotensive patients with
acute pulmonary embolism (PE).
Background Risk stratification of initially normotensive patients with PE on the basis of right ventricular dysfunction or injury
remains controversial. Previous studies investigating biomarkers or imaging modalities included unselected pa-
tients, some of whom presented with cardiogenic shock.
Methods We included 126 consecutive normotensive patients with confirmed PE. Complicated 30-day outcome was de-
fined as death, resuscitation, intubation, or use of catecholamines. Long-term survival was assessed by follow-up
clinical examination.
Results During the first 30 days, 9 (7%) patients suffered complications. These patients had higher baseline H-FABP values
(median, 11.2 ng/ml [interquartile range: 8.0 to 36.8 ng/ml]) compared with patients with an uncomplicated course
(3.4 ng/ml [2.1 to 4.9 ng/ml]; p  0.001). H-FABP values were above the calculated (by receiver operating character-
istic curve analysis) cutoff value of 6 ng/ml in 29 patients. Eight (28%) of them suffered complications versus 1 of 97
patients with low H-FABP (negative predictive value, 99%; p  0.001). By logistic regression, elevated (6 ng/ml)
H-FABP was associated with a 36.6-fold increase in the death or complication risk. The combination of H-FABP with
tachycardia was a particularly useful prognostic indicator. H-FABP also predicted long-term mortality over 499 (inter-
quartile range: 204 to 1,166) days (hazard ratio: 3.6; 95% confidence interval: 1.6 to 8.2; p  0.003).
Conclusions The H-FABP might be a useful biomarker for risk stratification of normotensive patients with acute PE. (J Am
Coll Cardiol 2010;55:2150–7) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.078h
t
f
i
t
(
m
d
i
w
i
1cute pulmonary embolism (PE) is a relatively frequent
ardiovascular emergency (1–3) and a major cause of mor-
idity and mortality in the population (4). At an average
ase fatality rate of 11% (1), venous thromboembolism is
esponsible for up to 15% of all in-hospital deaths (5).
owever, early or in-hospital death rates might vary widely,
ostly depending on the clinical severity of PE at presen-
ation (1,6). Accordingly, recent guidelines have proposed
mmediately classifying patients presenting with acute PE
nto a high-risk and a non–high-risk group (7). Patients
elonging to the “high-risk” group are those presenting with
rom the Department of Cardiology and Pulmonology, Georg August University of
oettingen, Goettingen, Germany. The study was supported by a grant from the
niversity of Goettingen (Heidenreich von Siebold Programm) to CD. Drs. Dellas
nd Puls contributed equally to this work.e
Manuscript received June 24, 2009; revised manuscript received October 13, 2009,
ccepted October 17, 2009.emodynamic instability (i.e., cardiogenic shock or persis-
ent arterial hypotension due to overt right ventricular [RV]
ailure). The treatment of these patients should definitely
nclude immediate thrombolysis or mechanical removal of the
hrombus in addition to standard heparin anticoagulation
7,8). By contrast, the optimal management of initially nor-
otensive patients with “non–high-risk” PE is less clearly
efined. In particular, further risk stratification of this seem-
ngly stable group, focusing on the identification of patients
ho present with (subclinical) RV dysfunction or myocardial
njury and might have an “intermediate” death risk of 3% to
5% (9–11), continues to pose a challenge in clinical practice.
See page 2158
Over the past years, a number of studies evaluated the use of
chocardiography, computed tomography, and N-terminal
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May 11, 2010:2150–7 H-FABP in Normotensive Pulmonary Embolismro-brain natriuretic peptide (NT-proBNP) for the detection
f RV dysfunction and the use of the cardiac troponins T and
for diagnosis of myocardial injury resulting from acute PE.
ecent meta-analyses of these studies generally confirmed the
rognostic value of these modalities but also brought to light
he marked heterogeneity and the numerous methodological
imitations of the individual studies (7,10–12). An important
bstacle to translating their data into a prognostic algorithm for
linical practice is that the vast majority of these studies
ncluded unselected (i.e., both high-risk and non–high-risk)
atients with PE, instead of focusing on the risk stratifica-
ion of the normotensive group.
Heart-type fatty acid-binding protein (H-FABP) is an
arly, highly sensitive marker of myocardial injury that has
een evaluated for emergency triage of patients with acute
oronary syndromes (13). Fatty acid-binding proteins are
elatively small cytoplasmic proteins (12 to 15 kDa) that are
bundant in tissues with active fatty acid metabolism,
ncluding the heart (14). After myocardial cell damage,
-FABP diffuses much more rapidly than troponins
hrough the interstitial space and appears in the circulation
s early as 90 min after symptom onset, reaching its peak
ithin 6 h (13). Recent studies in unselected patients with
cute PE suggested that H-FABP levels on admission
ight predict an adverse early clinical outcome with a
ensitivity and specificity superior to that of cardiac tro-
onins or natriuretic peptides (15,16). Moreover, H-FABP
evels were associated with the risk of death during long-
erm follow-up in patients with chronic thromboembolic
ulmonary hypertension (17). On the basis of these prom-
sing observations, we conducted the present study to
etermine whether H-FABP, alone or in combination with
linical or echocardiographic findings, might reliably predict
poor early and long-term prognosis in normotensive
atients with acute PE and thus help identify a true
intermediate-risk” group.
ethods
atient population and study design. We prospectively
ollowed consecutive patients who were diagnosed with
cute symptomatic PE (symptom onset, 4 weeks), at the
niversity Hospital of Goettingen over a 42-month period
between 2003 and 2007), and who were normotensive on
dmission. Of 187 patients with confirmed PE, 61 were not
onsidered for further analysis, because they met at least 1 of
he following exclusion criteria: 1) hemodynamic instability
i.e., persistent arterial hypotension or shock), defined as
ystolic blood pressure 90 mm Hg or a pressure drop of
40 mm Hg for 15 min at presentation if not caused by
ew-onset arrhythmia, hypovolemia, or sepsis (6) (n  24);
) denial or withdrawal of written consent for participation
n the study (n  4); 3) lost to follow-up (n  14); and 4)
nexpected or accidental diagnosis of PE (patients under-
oing diagnostic tests for another suspected disease) or PE poinciding with acute decom-
ensation of left ventricular (LV)
ailure or acute myocardial in-
arction (n  19).
The time period covered by
he present study (2003 to 2007)
artly overlapped with that (2003
o 2005) of a previous publica-
ion by our own group (15); of
hat latter patient population
n  107), 73 patients were also
ncluded in the present study,
hereas 34 were excluded due to
emodynamic instability (n 
0), loss to follow-up (n  14),
nd acute PE coinciding with
cute decompensation of LV
ailure or acute myocardial in-
arction (n  10). Between 2005
nd 2007, 53 additional patients were included. Thus, a
otal of 126 patients were finally considered for analysis.
The diagnostic workup for patients with suspected acute
E complied with existing guidelines during the study
eriod (18). Patients with high clinical (pre-test) probability
f PE on the basis of the standardized Wells Score (19) and
hose with intermediate or low clinical probability and a
ositive D-dimer test using a quantitative assay (Tina-
uant, Roche Diagnostics, Germany) underwent an imag-
ng procedure, preferably multidetector-row (64-slice) com-
uted tomography, to confirm the disease (88 patients; 70%
f the study population). Alternatively, in 31 (25%) patients
E was confirmed by a diagnostic ventilation-perfusion
ung scan. In 5 patients (4%), the diagnosis was based on the
atients’ clinical presentation and the confirmation of deep
ein thrombosis by compression ultrasonography. Pulmo-
ary angiography was rarely necessary to confirm PE (2
atients; 2%).
The study protocol strongly recommended a transtho-
acic echocardiogram within 2 h of PE diagnosis. Of 112
atients (89% of the study population) who underwent
ardiac ultrasound, 44 (39%) were diagnosed with RV
ysfunction. The latter finding was prospectively defined as
ilation of the RV (end-diastolic diameter 30 mm from
he parasternal view or a RV/LV diameter ratio 1.0 from
he subcostal or apical views), combined with right atrial
ypertension (absence of the inspiratory collapse of the
nferior vena cava) in the absence of LV or mitral valve
isease (15).
In all cases, blood was drawn immediately for measure-
ent of baseline (admission) biomarker levels before further
iagnostic workup. After confirmation of the diagnosis,
atients were asked to sign the informed consent form.
ubsequently, complete data on baseline clinical, hemody-
amic, and laboratory parameters were obtained with a
tandardized questionnaire by investigators unaware of the
Abbreviations
and Acronyms
AUC  area under the
curve
CI  confidence interval
cTnT  cardiac troponin T
H-FABP  heart-type fatty
acid binding protein
IQR  interquartile range
LV  left ventricle/
ventricular
OR  odds ratio
PE  pulmonary embolism
ROC  receiver operating
characteristic curve
RV  right ventricle/
ventricularatients’ biomarker levels.
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H-FABP in Normotensive Pulmonary Embolism May 11, 2010:2150–7Thirty-day clinical follow-up data were obtained from all
atients included in the study. A complicated 30-day
utcome was defined as death or at least 1 of the following
ajor adverse events: 1) need for catecholamine adminis-
ration (except for dopamine at a rate of 5 g/kg/min) to
aintain adequate tissue perfusion and prevent or treat
ardiogenic shock; 2) endotracheal intubation; or 3) cardio-
ulmonary resuscitation. Long-term survival was assessed
y follow-up examinations at 6-month intervals after PE
iagnosis.
Biomarker levels were not communicated to the clinicians
nvolved in the care of the study patients, and they were not
sed to guide patient management or to monitor the effects
f treatment during the hospital stay or at any time during
he follow-up period. The study protocol was approved by
he ethics committee of the University of Goettingen.
aboratory parameters and biomarker testing. Venous
lasma and serum samples were collected on admission and
4 h thereafter and immediately stored at 80°C. Samples
ere later analyzed in batches after a single thaw. Plasma
evels of H-FABP (dilution 1:5) were measured by a
olid-phase enzyme-linked immunoadsorbent assay on the
asis of the sandwich principle (HyCult Biotechnology,
den, the Netherlands). Cardiac troponin T (cTnT) and
T-proBNP levels were determined in plasma samples with
uantitative electrochemiluminescence immunoassays
Elecsys 1010/2010 analyzer, Roche Diagnostics, Mann-
eim, Germany) as described (20,21). All other laboratory
easurements were performed at the Department of Clin-
cal Chemistry, University of Goettingen, with standard
aboratory techniques. Renal insufficiency was defined as a
lomerular filtration rate 60 ml/min/1.73 m2. Glomerular
ltration rate was calculated from the “four-variable” Mod-
fication of Diet in Renal Disease Study equation (22).
tatistical analysis. With the modified Kolmogorov-
mirnov test (Lilliefors test), the continuous variables tested
n the present study were found not to follow a normal
istribution; therefore, they are presented as medians with
orresponding 25th and 75th percentiles and were com-
ared with the unpaired Mann-Whitney U test. Categorical
ariables were compared with Fisher exact test. Prognosti-
ally relevant cutoff values of prespecified clinical (heart rate)
nd laboratory (H-FABP) parameters were derived from
eceiver operating characteristic (ROC) curve analysis,
hich also was used to determine the area under the curve
AUC) (c-statistic). The optimal cutoff point was chosen as
he cutoff value at which 0.5 (sensitivity specificity) was
aximal. By contrast, a value of 0.04 ng/ml was prospec-
ively defined as indicating an elevated cTnT concentration
s proposed by the manufacturer; for NT-proBNP, the
utoff level was prospectively set at 1,000 pg/ml on the basis
f our previous findings in patients with PE (20,23).
The prognostic relevance of H-FABP levels and other
aseline parameters with regard to 30-day outcome was
stimated with logistic regression analysis with the calcu-
ated or prospectively defined cutoff values. The results are wresented as odds ratios (ORs) with the corresponding 95%
onfidence intervals (CIs). To identify predictors of long-
erm mortality, Cox proportional hazards regression analysis
as performed with Wald’s test; these results are presented
s hazard ratios with corresponding 95% CIs. Survival rates
ere estimated by the Kaplan-Meier method, and statistical
omparison was performed with the log-rank test. All tests
ere 2-sided and used a significance level of 0.05.
The ROC curves from different biomarkers were com-
ared with the software Analyse-it (version 2.21 Excel 12,
nalyse-it Software, Ltd., Leeds, United Kingdom), which
pplies the method of DeLong et al. (24). All other analyses
ere performed with the SPSS 17.0 software (SPSS, Inc.,
hicago, Illinois) and GraphPad Prism 4 (GraphPad Soft-
are, San Diego, California).
esults
-FABP levels on admission predict 30-day outcome in
ormotensive patients with PE. The baseline clinical
haracteristics and biomarker levels of the study population
re summarized in Table 1. The H-FABP concentrations
n admission ranged from 0.39 to 217.5 ng/ml with a
edian value of 3.4 ng/ml (interquartile range [IQR] 2.2 to
.4 ng/ml). During the first 30 days, 9 (7%) patients suffered
ajor complications: 6 patients died, 5 underwent cardio-
ulmonary resuscitation, and 7 required catecholamines
nd/or endotracheal intubation. Patients who developed
omplications had elevated H-FABP values on admission
median, 11.2 ng/ml; IQR 8.0 to 36.8 ng/ml) compared
ith patients with an uncomplicated course (3.4 [IQR 2.1
o 4.9] ng/ml; p  0.001). In contrast, neither the baseline
TnT concentrations nor those of NT-proBNP differed
ignificantly between patients suffering complications
ithin 30 days and those with an uncomplicated course
cTnT, 0.12 [0.009 to 0.26] ng/ml vs. 0.009 [0.009 to 0.04]
g/ml; p 0.072; NT-proBNP, 1,914 [IQR 525 to 25,462]
g/ml vs. 980 [IQR 181 to 2,630] pg/ml; p  0.10).
Receiver operating characteristic analysis further sug-
ested that H-FABP levels on admission are a powerful
redictor of 30-day outcome in normotensive patients with
cute PE (Fig. 1). The calculated AUC was 0.89 (95% CI:
.77 to 1.01) for H-FABP, 0.68 (95% CI: 0.47 to 0.9) for
TnT, and 0.67 (95% CI: 0.48 to 0.85) for NT-proBNP.
he AUC for H-FABP was significantly higher than the
UC for NT-proBNP (p  0.017), in a comparison of all
AUCs (24); other p values were p  0.085 for H-FABP/
TnT and p  0.834 for cTnT/NT-proBNP). With ROC
nalysis, a concentration of 6.09 ng/ml was identified as the
est cutoff level for H-FABP in our study population.
otably, this is almost identical to the cutoff value of 6
g/ml found in previous studies that tested H-FABP in
nselected patients with acute PE (15) and in patients with
cute coronary syndromes (25,26).
In the present study, 29 (23%) normotensive patients
ith acute PE had H-FABP concentrations in plasma 6
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May 11, 2010:2150–7 H-FABP in Normotensive Pulmonary Embolismg/ml on admission. As shown in Table 1, patients with
levated H-FABP were older, had higher baseline circulat-
ng levels of cTnT or NT-proBNP, and were more likely to
resent with syncope as the leading symptom and with acute
V dysfunction in the echocardiogram. During the first 30
ays, 8 (28%) patients with initially elevated H-FABP had
complicated course; 4 of them died during this period. In
ontrast, only 1 of the 97 patients with H-FABP 6 ng/ml
uffered complications (p  0.0001). Thus, with the cutoff
alue of 6 ng/ml, H-FABP had a sensitivity of 0.89 (95%
I: 0.52 to 0.99), specificity of 0.82 (95% CI: 0.74 to 0.89),
ositive predictive value of 0.28 (95% CI: 0.13 to 0.47), and
egative predictive value of 0.99 (95% CI: 0.94 to 0.99) with
egard to an adverse 30-day outcome.
Univariable logistic regression demonstrated that patients
ith H-FABP 6 ng/ml at presentation had a 36.6-fold
ncreased risk for 30-day complications (p 0.001) (Table 2).
he only other baseline parameters found to predict an
dverse outcome were an elevated heart rate 94 beats/min
cutoff value derived by ROC analysis; AUC: 0.74 [95% CI:
.651 to 0.89]) and syncope. In contrast, neither NT-
roBNP (p  0.331) nor cTnT (p  0.087) concentrations
bove the predefined cutoff values of 1,000 pg/ml and 0.04
g/ml, respectively, seemed to predict 30-day outcome in
ormotensive patients with PE. When tested by multivari-
ble analysis (including only the significant predictors from
he univariable model), H-FABP remained an independent
redictor of complicated 30-day outcome (H-FABP eleva-
ion, OR: 25.9 [95% CI: 2.9 to 229.3], p  0.003;
achycardia 94 beats/min, OR: 7.9 [95% CI: 0.9 to 73.9],
 0.068; syncope: OR: 2.7 [95% CI: 0.5 to 14.6], p 
.259).
Finally, repeated biomarker measurements revealed that
one of the 62 tested patients who had H-FABP levels 6
g/ml on admission developed a positive test 24 h later or
aseline Characteristics of the Study PopulationTable 1 Baseline Characteristics of the Study Population
Parameter
All Patients
(n  126)
Age (yrs) 67 (51–74)
Surgery within 14 days 20 (16%)
Trauma within 14 days 7 (6%)
Malignant tumor 21 (17%)
History of DVT 42 (33%)
History of PE 20 (16%)
Dyspnea 117 (93%)
Syncope 20 (16%)
Heart rate (beats/min) 92 (80–110)
GFR (ml/min/1.73 m2) 76.4 (55.1–94.9)
H-FABP (ng/ml) 3.4 (2.1–5.4)
NT-proBNP (pg/ml) 1,046 (188–2,685)
cTnT (ng/ml) 0.009 (0.009–0.048)
RV dysfunction on echocardiography 44/112 (39%)
ategorical variables are expressed as absolute n (%); continuous variables are expressed as med
cTnT  cardiac troponin T; DVT  deep venous thrombosis; GFR  glomerular filtration rate; Huffered cardiovascular complications during the first day in bhe hospital. Thus, a normal H-FABP on admission seemed
ufficient to rule out an adverse 30-day outcome in normo-
ensive patients with acute PE. In contrast, the biomarker
est became positive after 24 h in 5 of 60 patients with an
nitially negative cTnT test and in 8 of 42 patients with
nitially “low” (1,000 pg/ml) NT-proBNP levels. In each
ne of these latter groups, 1 patient suffered complications
uring the first 24 h (i.e., between the first and the second
iomarker test).
ombined approach with clinical parameters and
iomarker levels for risk assessment of normotensive
E. We tested the hypothesis that biomarker levels and
articularly H-FABP might have an additive prognostic
alue when combined with baseline clinical parameters in
atients with acute PE. As mentioned in the preceding text
nd shown in Table 2, a heart rate of 94 beats/min was
nivariably associated with a 10.6-fold increase in the risk of
hort-term complications compared with patients with a
ower heart rate. However, of 40 patients with tachycardia
ut normal (6 ng/ml) H-FABP levels on admission, only
(2.5%) developed complications, whereas 39% of patients
ith tachycardia and H-FABP6 ng/ml had a complicated
ourse (Fig. 2). Logistic regression confirmed that patients
ith the combination of tachycardia and H-FABP 6
g/ml had a 33.4-fold elevated risk of an adverse 30-day
utcome (p  0.0001). The H-FABP concentrations at
aseline also seemed to increase the prognostic value of
ther clinical (e.g., syncope) or echocardiographic (RV
ysfunction) findings in normotensive patients with PE
Fig. 2).
-FABP levels on admission also predict long-term
rognosis after PE. The median follow-up time after the
ndex episode of acute PE was 499 days (IQR 204 to 1,166
ays). Twenty six patients (21%) died during this period.
atients who died during follow-up had significantly higher
H-FABP >6 ng/ml
(n  29)
H-FABP <6 ng/ml
(n  97) p Value
71 (57–80) 65 (47–72) 0.02
5 (17%) 15 (15%) 0.78
2 (7%) 5 (5%) 0.66
6 (21%) 15 (15%) 0.57
7 (24%) 35 (36%) 0.27
0 20 (21%) 0.007
25 (86%) 92 (95%) 0.21
9 (31%) 11 (11%) 0.019
100 (85–110) 90 (78–110) 0.12
57.1 (41.1–83.2) 78.3 (61.8–95.5) 0.010
9.9 (6.7–14.0) 3.0 (1.7–3.8) —
1,988 (425–7,930) 810 (173–2,431) 0.005
0.03 (0.009–0.24) 0.009 (0.009–0.03) 0.004
17/28 (61%) 27/84 (32%) 0.013
ith the corresponding interquartile range (25th to 75th percentile).
heart-type fatty acid-binding protein; PE  pulmonary embolism; RV  right ventricular.aseline levels of H-FABP (median 5.5 ng/ml; IQR 1.4 to
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H-FABP in Normotensive Pulmonary Embolism May 11, 2010:2150–71.2 ng/ml) compared with survivors (3.4 [IQR 2.0 to 4.8]
g/ml; p  0.006). Baseline NT-proBNP values also were
igher in nonsurvivors as opposed to the patients who
urvived (2,233 [IQR 14 to 12,180] pg/ml vs. 788 [IQR 173
o 2,374] pg/ml; p  0.001), whereas cTnT levels on
dmission did not differ between nonsurvivors and survivors
0.013 [IQR 0.007 to 0.19] ng/ml vs. 0.009 [IQR 0.009 to
.04] ng/ml; p  0.55). By univariable Cox regression
nalysis, patients with H-FABP 6 ng/ml on admission
ad a 4.5-fold increased risk for death during long-term
ollow-up as calculated (p  0.0001) (Table 3). Further
Figure 1 Prognostic Sensitivity and Specificity
of H-FABP, cTnT, and NT-proBNP
Receiver operating characteristic curves for heart-type fatty acid-binding protein
(H-FABP), cardiac troponin T (cTnT), and N-terminal pro-brain natriuretic peptide
(NT-proBNP) levels on admission with regard to a complicated 30-day outcome.
AUC  area under the curve.aseline parameters univariably predicting long-term mor-
Uality were tachycardia 94 beats/min and the presence of a
alignant tumor (Table 3) but not the diagnosis of RV
ysfunction on echocardiography (p  0.664). Multivari-
ble analysis including the significant predictors from the
nivariable model revealed that elevated H-FABP levels on
dmission remained, besides the presence of a malignant
umor, an independent predictor of long-term mortality
H-FABP 6 ng/ml, OR: 3.6 [95% CI: 1.6 to 8.2], p 
.002; malignant tumor, OR: 5.3 [95% CI: 2.4 to 11.5], p 
.0001; tachycardia 94 beats/min, OR: 1.9 [95% CI: 0.8 to
.7], p  0.138). Kaplan-Meier analysis further showed that
atients with baseline H-FABP levels6 ng/ml had a reduced
robability of long-term survival (Fig. 3, upper panel). In
ontrast, neither elevation of cTnT nor elevation of NT-
roBNP at presentation predicted an increased probability of
eath during the follow-up period (Fig. 3).
iscussion
his study evaluated the usefulness of cardiac biomarkers
nd particularly H-FABP in the risk stratification of acute
E. In contrast to previously published studies that included
nselected patients across the entire clinical spectrum of PE
everity (10–12), the present study focused on initially
ormotensive patients and directly addressed the possible
xistence of an “intermediate-risk” group as proposed by
ecent guidelines (7). In 126 consecutive patients with
onfirmed PE who presented without hemodynamic insta-
ility (i.e., persistent arterial hypotension or shock), we
ound that elevated (6 ng/ml) H-FABP levels on admis-
ion were strongly associated with the 30-day death and
omplication rate. The prognostic value of H-FABP
eemed superior to that of previously validated biomarkers
uch as cardiac troponins and natriuretic peptides and to the
etection of RV dysfunction on echocardiography. More-
ver, elevated H-FABP concentrations at presentation were
elated to long-term mortality after acute PE.
In acute PE, persistent arterial hypotension or cardio-
enic shock on admission is clearly associated with high
n-hospital mortality (5,27). However, the majority of
atients subsequently diagnosed with acute PE present with
ormal arterial pressure. Although further risk stratification
f these patients into an “intermediate-risk” and a “low-risk”
roup is supported by current guidelines (7), the optimal
redictors of Complicated 30-Day OutcomeTable 2 Predictors of Complicated 30-Day Outcome
Parameter OR (95% CI) p Value
Heart rate 94 beats/min 10.6 (1.3–87.2) 0.029
Syncope 5.1 (1.2–20.8) 0.025
Malignant tumor 2.8 (0.6–12.0) 0.179
H-FABP 6 ng/ml 36.6 (4.3–308) 0.001
cTnT 0.04 ng/ml 3.3 (0.4–13.1) 0.087
GFR 60 ml/min 3.2 (0.8–12.7) 0.097
RV dysfunction (echocardiography) 2.8 (0.6–12.3) 0.178nivariable logistic regression analysis.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
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May 11, 2010:2150–7 H-FABP in Normotensive Pulmonary Embolismools and strategies to achieve this goal remain controversial.
chocardiography is an appropriate modality for diagnosing
V dysfunction in a patient with cardiogenic shock sus-
ected of having massive PE, and it might also be of
rognostic value in normotensive patients (9). By contrast,
chocardiographic studies in PE have been criticized for
heir heterogeneity and lack of standardized criteria (28),
nd a recent meta-analysis reported a low overall specificity
Figure 2 Combination of H-FABP With Clinical Parameters
The number of patients with complications and the overall number of patients
are given, along with percentages, for each column. H-FABP  heart-type fatty
acid binding protein; HR  heart rate; RV  right ventricular.57%) and positive predictive value (58%) of the echocar-iogram in predicting an adverse outcome (12). In the
resent study, 39% of normotensive patients had echocar-
iographic findings suggesting RV dysfunction, but overall
chocardiography was, by itself, not found to predict a
ignificantly elevated risk of death or complications within
he first 30 days. Right ventricular dysfunction can also be
aseline Parameters Predictingong-Term Mortality Aft r Acute PETable 3 Baseline arameters PredictingLong-Term Mortality After Acute PE
Parameter HR (95% CI) p Value
Heart rate 94 beats/min 2.8 (1.2–6.5) 0.015
Syncope 2.2 (0.9–5.1) 0.082
Malignant tumor 5.6 (2.6–12.3) 0.0001
H-FABP 6 ng/ml 4.5 (2.0–9.8) 0.0001
NT-proBNP 1,000 pg/ml 2.1 (0.9–4.7) 0.089
nivariable Cox regression analysis.
CI  confidence interval; HR  hazards ratio; other abbreviations as in Table 1.
Figure 3 Probability of Long-Term Survival in Patients With
or Without Elevation of H-FABP, cTnT, and NT-proBNP
Biomarker levels were dichotomized, and elevated concentrations were defined
as those 6 ng/ml for H-FABP, 0.04 ng/ml for cTnT, and 1,000 pg/ml for
NT-proBNP. Red lines  elevated values; blue lines  normal values; p values
were calculated by the log-rank test. Abbreviations as in Figure 1.
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H-FABP in Normotensive Pulmonary Embolism May 11, 2010:2150–7ssessed on the basis of the circulating levels of brain
atriuretic peptides. However, although elevated brain na-
riuretic peptides and NT-proBNP concentrations are gen-
rally related to a poor in-hospital outcome (11), their
ositive predictive value is low, and prospectively validated
utoff values are lacking (11,29,30). Furthermore, elevated
oncentrations of brain natriuretic peptides can be found in
ther conditions and comorbidities, including LV dysfunction,
lder age, renal impairment, and chronic lung disease (31).
Besides RV dysfunction, evidence of myocardial injury
lso has been shown to be of prognostic relevance in patients
ith PE. Cardiac troponins are highly sensitive and specific
ndicators of myocardial cell damage, and elevated troponin
evels were correlated with in-hospital mortality or compli-
ations in unselected patients with acute PE (21). A recent
eta-analysis generally confirmed the prognostic value of
levated troponin levels in acute PE (10). However, repet-
tive troponin measurements (i.e., beyond those obtained on
dmission) might be required to increase the negative
redictive value of this biomarker (15,32). Moreover, and
mportantly, cardiac troponins possess a low positive pre-
ictive value (30), and the results of the present study
ndicate that they might be less suitable for predicting either
hort-term or long-term outcome in the subgroup of ini-
ially normotensive (non–high-risk) patients with acute PE.
Heart-type fatty acid-binding protein is an early indicator
f myocardial injury that has been evaluated in the diagnosis
nd triage of acute coronary syndromes. Compared with
ardiac troponins, H-FABP testing offers a number of
otential advantages (discussed in Puls et al. [15]) that are
elated to its small molecular size (very early release after
njury), its relative myocardial specificity that resembles that
f the myocardial band isoenzyme of creatine kinase, and its
onfinement to the cytoplasmic space. The release charac-
eristics of H-FABP from injured myocardium closely
esemble those of myoglobin, but H-FABP seems to
ossess both higher sensitivity and higher cardiospecificity
ompared with the latter biomarker. The concentration of 6
g/ml has been proposed as an upper reference level of
-FABP in previous studies (25,26).
Recently, H-FABP was tested in 2 studies that included
nselected (i.e., both normotensive and hypotensive) pa-
ients with PE. Elevated H-FABP values were superior to
TnT, NT-proBNP, and myoglobin in risk assessment with
egard to 30-day outcome (15,16). However, patients who
resent with persistent arterial hypotension or shock are
learly at high risk of early death and do not necessitate
urther risk stratification with biomarker testing. Therefore,
nd in contrast to the previous reports, we focused on the
utcome of initially normotensive patients with PE to
istinguish the intermediate-risk from the low-risk group
7). In this patient population, we could demonstrate that
levated H-FABP is a strong predictor both of an adverse
0-day outcome and of long-term mortality. In fact,
-FABP 6 ng/ml at baseline was associated with a7-fold increase in the 30-day complication risk and a r.5-fold increase in the risk of death at long-term follow-up
median period, 499 days), whereas normal H-FABP values
irtually excluded an adverse clinical outcome (negative
redictive value, 99%). Importantly, negative H-FABP
alues on admission remained negative over the first 24 h,
nd thus repetitive measurements of the biomarker might
ot be necessary to increase its prognostic value.
At the present stage, we can only speculate on how
xactly elevated H-FABP levels on admission might (also)
ave affected long-term outcome after acute PE. In this
egard, the exclusion of 14 patients who were lost to
ollow-up might be a potential limitation of our study. It is
ostulated that some novel biomarkers are capable of
ntegrating prognostic information related to various co-
orbidities, including cancer, and might thus serve as
global” indicators of poor outcome after acute PE (23).
lthough preliminary data suggest that H-FABP might
lso reflect the aggressiveness and prognosis of some carci-
omas, the most plausible explanation of our findings might
e related to the persistence of pulmonary hypertension
fter acute PE. In this regard, we have previously shown
hat elevated H-FABP levels on admission independently
redicted an adverse outcome in patients with chronic
hromboembolic pulmonary hypertension (17).
Weighted scores combining baseline clinical parameters
ave been evaluated in the risk stratification of acute PE and
eem particularly useful for the identification of low-risk
atients who might be eligible for early discharge and home
reatment (5,33). In search of an optimal strategy for
dentifying a true “intermediate-risk” group with RV dys-
unction despite normal blood pressure on admission, we
ound that the combination of a positive (6 ng/ml)
-FABP-test with an elevated heart rate (94 beats/min)
t presentation was a strong, highly significant predictor of
eath or complications in the acute phase. This simplified
risk score” might be a particularly attractive option for
linicians, because bedside H-FABP tests are now commer-
ially available.
It should be noted that, although the incidence of death
r major complications in our study corresponds to that
reviously reported for normotensive (non–high-risk) PE
atients (9–11), the low absolute numbers of end points
uring short- and long-term follow-up (9 and 26 events,
espectively) might limit the interpretation of our multiva-
iable regression models.
onclusions
-FABP seems to be a useful biomarker for risk stratifica-
ion in normotensive patients with acute PE. A single
easurement on admission, as early as 60 to 90 min after
he onset of symptoms, might be sufficient to classify
ormotensive patients with confirmed PE into a low-risk or
n intermediate-risk group and might thus guide manage-
ent strategies in the absence of shock. On the basis of ouresults and those of previous studies, the therapeutic impli-
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ith baseline clinical parameters, deserve to be addressed by
prospective management study.
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